Article Text

Download PDFPDF
Case report
Kasabach-Merritt phenomenon with cellulitis in infant
  1. Ariyati Yosi1,
  2. Abdullah Afif Siregar2,
  3. Yasmine Siregar2 and
  4. Widyaningsih Oentari1
  1. 1Department of Dermatology and Venereology, Universitas Sumatera Utara Fakultas Kedokteran, Medan, Indonesia
  2. 2Cardiology Department, Universitas Sumatera Utara Fakultas Kedokteran, Medan, Indonesia
  1. Correspondence to Ariyati Yosi; yosiariyati{at}gmail.com

Abstract

Kasabach-Merritt phenomenon (KMP) is consumptive coagulopathy in large vascular lesion. This condition is specific in kaposiform haemangioendothelioma (KHE) and tufted angioma, associated with high mortality rate. This condition often involves the limbs, trunk and retroperitoneum. The clinical features that are usually found are purpura, oedema, induration and ecchymosis. A boy baby aged 9 months presented with a history of violaceous tumour that appeared on his left leg at birth that became enlarged since 6 months ago that caused discrepancy between both of his legs. The patient has his left leg massaged through alternative treatment, causing it became bruised and wounded. Blood examination showed normocytic normochromic anaemia with severe thrombocytopenia and high D-dimer. The patient was diagnosed with KMP with cellulitis and treated with oral corticosteroid, propranolol and antibiotics. Diagnosis of KMP can be made through clinical and laboratory findings. Combination therapy with corticosteroid and propranolol can be considered for KMP treatment.

  • dermatology
  • cardiovascular medicine

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors AY: Patient’s examination and diagnosis, discuss planning for topical medication for skin condition in patient, conception and design, analysis and interpretation of data. AAS: Patient’s examination and diagnosis, discuss planning for systemic medication in patient, conception and design, analysis and interpretation of data. YS and WO: Patient follow-up, reporting the data, analysis and interpretation of data.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.